NCT07467772 2026-04-21
Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Dana-Farber Cancer Institute
Phase 2 Recruiting
Clinical Trials
18 trialsNCT06120283 2026-04-15
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06638307 2026-04-13
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Recruiting
NCT07198724 2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05386108 2026-04-06
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06382948 2026-04-03
ADELA
MedSIR
Phase 3 Recruiting
NCT06492616 2026-03-27
ELEGANT
Stemline Therapeutics, Inc.
Phase 3 Recruiting
NCT06923527 2026-03-27
Circulating Tumor DNA
Yale University
Phase 2 Recruiting
NCT05573126 2026-03-20
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Phase 1/2 Recruiting
NCT07209449 2026-03-18
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07222215 2026-01-22
CAPELA
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06691035 2025-12-04
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT06201234 2025-12-01
ELEMENT
GBG Forschungs GmbH
Phase 2 Recruiting
NCT07159451 2025-12-01
POP-ELA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT06062498 2025-10-20
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Phase 2 Recruiting
NCT05512364 2025-08-19
TREAT ctDNA
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Recruiting